Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI plus ramucirumab versus placebo in previously bevacizumab-treated metastatic colorectal cancer
NL-OMON36541Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing FOLFIRI + ramucirumab with FOLFIRI + placebo (2 arms). Primary endpoint: Overall survival. Started Feb 2012; status: active, not recruiting.
02
Drugs
ramucirumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON36541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36541.